Further options for your experiments:
Application schemes and assay conditions can be adapted to your needs.
Whole-cell recordings or single-channel analysis in various expression systems
(HEK 293, CHO, Neuroblastoma etc.) can be conducted to test the effects of drugs on voltage-gated or ligand-gated ion channels.
B'SYS currently operates 4 automated patch clamp devices (Sophion Qpatch™).
Please contact us for details or offers → Contact
| Target | Gene | Species | Disorder | Manual | Automated | ||
|---|---|---|---|---|---|---|---|
| NaV1.1 | SCN1A | human | Epilepsy | 0 | 0 |  |
|
| NaV1.2 | SCN2A | human | Autism / Epilepsy / Intellectual disability | 0 | 0 |
|
|
| NaV1.3 | SCN3A | human | Epilepsy / Pain | 0 | 0 | |
|
| NaV1.4 | SCN4A | human | Myotonia | 0 | 0 |
|
|
| NaV1.4 | SCN4A | human | Myotonia | 0 | 0 |
|
|
| NaV1.5 | SCN5A | human | LQT Syndrome 3 | 0 | 0 | |
|
| NaV1.5 | SCN5A | human | LQT Syndrome 3 | 0 | 0 | |
|
| NaV1.5 / ATXII-activated late current | SCN5A | human | LQT Syndrome 3 | 0 | 0 | |
|
| NaV1.5 / late current | SCN5A | human | LQT Syndrome 3 | 0 | 0 | |
|
| NaV1.5 / peak current | SCN5A | human | LQT Syndrome 3 | 0 | 0 | |
|
| NaV1.5 duo | SCN5A | human | LQT Syndrome 3 | 0 | 0 |
|
|
| NaV1.5 big late | SCN5A L409C/A410W | human | LQT Syndrome 3 | 0 | 0 |
|
|
| NaV1.5 ΔKPQ | SCN5A ΔKPQ | human | LQT Syndrome 3 | 0 | 0 | |
|
| NaV1.6 | SCN8A | human | Epilepsy / Intellectual disability | 0 | 0 | |
|
| NaV1.7 | SCN9A | human | Pain | 0 | 0 |
|
|
| NaV1.7 | SCN9A | human | Pain | 0 | 0 |
|
|
| NaV1.8 | SCN10A/SCN3B | human | Neuropathy | 0 | 0 |
|
|
| NaV1.9 | SCN11A | human | Pain | 0 | 0 |
|
|
| Neuroblastoma whole sodium (TTX sensitive sodium channels) | 0 | 0 | |